Wen, Simeng <br/><br/>
ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.  [electronic resource] 

 -  Cancer letters  07 2016 
 - 377-86 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2016.01.057  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Androgen Antagonists--pharmacology<br/>Anilides--pharmacology<br/>Animals<br/>Antineoplastic Agents, Hormonal--pharmacology<br/>Benzamides<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Curcumin--analogs & derivatives<br/>Enhancer of Zeste Homolog 2 Protein--genetics<br/>Humans<br/>Male<br/>Mice, Nude<br/>Neoplasm Invasiveness<br/>Neoplastic Stem Cells--drug effects<br/>Nitriles--pharmacology<br/>Phenylthiohydantoin--analogs & derivatives<br/>Prostatic Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>STAT3 Transcription Factor--genetics<br/>Side-Population Cells--drug effects<br/>Signal Transduction--drug effects<br/>Tosyl Compounds--pharmacology<br/>Xenograft Model Antitumor Assays